.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,977,253

« Back to Dashboard

Claims for Patent: 6,977,253

Title: Methods for the treatment of bipolar disorder using carbamazepine
Abstract:Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.
Inventor(s): Kalali; Amir H. (San Diego, CA), Tulloch; Simon J. (Gaithersburg, MD)
Assignee: Shire Pharmaceutical Development Inc. (Rockville, MD)
Application Number:10/848,383
Patent Claims: 1. A method of treating a patient suffering from bipolar disorder comprising administering to said patient an initial daily dose of 100-800 mg of carbamazepine in extended release form and increasing said dose by daily increments of 100-400 mg until clinical efficacy is achieved, wherein the occurrence of adverse side effects is not greater than that which occurs when the daily dose is increased in weekly increments.

2. A method of treating a patient suffering from bipolar disorder comprising administering to said patient an initial daily dose of 100-800 mg carbamazepine in extended release form and increasing said daily dose by daily increments of 100-400 mg until clinical efficacy is achieved.

3. A method according to claim 2, wherein said method is used to treat a patient that suffers from manic episodes.

4. A method according to claim 2, wherein said method is used to treat a patient that suffers from mixed episodes.

5. A method according to claim 2, wherein carbamazepine is administered twice daily.

6. A method according to claim 2, wherein said initial dose is 200 mg.

7. A method according to claim 2, wherein said initial dose is 400 mg.

8. A method according to claim 2, wherein said initial dose is 600 mg.

9. A method according to claim 2, wherein said initial dose is 800 mg.

10. A method according to claim 2, wherein the daily dose increment is 100 mg.

11. A method according to claim 2, wherein the daily dose increment is 200 mg.

12. A method according to claim 2, wherein the daily dose increment is 300 mg.

13. A method according to claim 2, wherein the daily dose increment is 400 mg.

14. A method according to claim 2, further comprising administering to said patient lithium, valproate, chlorpromazine, olanzapine, lamotrigine, gabapentin or a combination thereof.

15. A method according to claim 1, wherein the period of time during which the daily dose is increased daily by increments is at least 6 days.

16. A method according to claim 1, further comprising continuing to treat said patient by administering the same daily dose as at which clinically efficacy is achieved or reducing said daily dose by daily increments to a lower level at which efficacy can be maintained.

17. A method according to claim 2, wherein the period of time during which the daily dose is increased by daily increments is at least 6 days.

18. A method according to claim 2, further comprising continuing to treat said patient by administering the same daily dose as at which clinically efficacy is achieved or reducing said daily dose by daily increments to a lower level at which efficacy can be maintained.

19. A method of treating a patient suffering from bipolar disorder comprising administering to said patient an initial daily dose of 100-800 mg of carbamazepine in extended release form and increasing said dose by daily increments until a final daily dose of 1,000-1,600 mg.

20. A method according to claim 19, wherein said initial daily dose is 100-400 mg.

21. A method according to claim 19, wherein said final daily dose is 1,200-1,600 mg.

22. A method according to claim 21, wherein said final daily dose is 1,200-1,400 mg.

23. A method according to claim 19, wherein said initial daily dose is 200 mg.

24. A method according to claim 21, wherein said initial daily dose is 200 mg.

25. A method according to claim 22, wherein said initial daily dose is 200 mg.

26. A method according to claim 19, wherein said initial daily dose is 400 mg.

27. A method according to claim 21, wherein said initial daily dose is 400 mg.

28. A method according to claim 22, wherein said initial daily dose is 400 mg.

29. A method according to claim 1, wherein the period of time during which the daily dose is increased by daily increments is at least 5 days.

30. A method according to claim 2, wherein the period of time during which the daily dose is increased by daily increments is at least 5 days.

31. A method according to claim 19, wherein the period of time during which the daily dose is increased by daily increments is at least 5 days.

32. A method according to claim 1, wherein carbamazepine is administered twice daily, the initial daily dose is 400 mg, and the daily dose increment is 200 mg.

33. A method according to claim 2, wherein carbamazepine is administered twice daily, the initial daily dose is 400 mg, and the daily dose increment is 200 mg.

34. A method according to claim 19, wherein carbamazepine is administered twice daily, the initial daily dose is 400 mg, and the daily dose increment is 200 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc